Article info
PDFAbstracts
Clinical pharmacy and clinical trials (including case series)
Off-label use of omalizumab in cases refractory to approved treatments
Citation
Off-label use of omalizumab in cases refractory to approved treatments
Publication history
- First published March 12, 2012.
Online issue publication
May 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions